secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2023-06-15T23:59:59+00:00
Accession:  0001628280-23-022271
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology's 2023 annual meeting results: all director nominees elected, BDO ratified, say-on-pay approved
--------------------------------------------------------------------------------

- Seven director nominees elected with votes ranging from 12.5M to 14.1M for; broker non-votes ~12.67M.
- Ratification of BDO USA as auditor for FY2023 approved with 26.56M for, 0.56M against, 0.18M abstain.
- Advisory vote on executive compensation frequency: 1-year option approved with 13.68M votes; board sets annual say-on-pay.
- Advisory vote on named executive officer compensation approved: 11.92M for, 2.42M against, 0.29M abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000162828023022271/0001628280-23-022271-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000162828023022271/crdf-20230615.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-022271

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer